We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based...
BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based...
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024;...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.28 | 5.69105691057 | 4.92 | 5.7 | 4.8 | 382615 | 5.17306212 | CS |
4 | -0.66 | -11.2627986348 | 5.86 | 6.045 | 4.63 | 188998 | 5.311006 | CS |
12 | -0.46 | -8.12720848057 | 5.66 | 8.84 | 4.63 | 161142 | 6.19182258 | CS |
26 | 1.84 | 54.7619047619 | 3.36 | 8.84 | 2.9106 | 183868 | 5.44817488 | CS |
52 | -0.47 | -8.28924162257 | 5.67 | 8.84 | 2.44 | 198493 | 5.36548317 | CS |
156 | -16.8 | -76.3636363636 | 22 | 45.56 | 2.44 | 207828 | 11.19403165 | CS |
260 | -16.8 | -76.3636363636 | 22 | 45.56 | 2.44 | 207828 | 11.19403165 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions